What is Amplia Therapeutics Limited's (ATX.AX) StockRank?

MoatMap's StockRank for Amplia Therapeutics Limited (ATX.AX) is 15/100, with a Strong Sell signal. This is a composite score combining Quality (40), Value (30), and Momentum (27) factor ranks across MoatMap's 20,000+ stock universe.

Does Amplia Therapeutics Limited have an economic moat?

Amplia Therapeutics Limited (ATX.AX) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Amplia Therapeutics Limited a buy, hold, or sell?

MoatMap's current signal for Amplia Therapeutics Limited (ATX.AX) is Strong Sell, based on a StockRank of 15/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Amplia Therapeutics Limited in?

Amplia Therapeutics Limited (ATX.AX) operates in the Healthcare sector, specifically the Biotechnology industry (Australia).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ATX.AX

STRONG SELL

Amplia Therapeutics Limited · Healthcare · Australia · $56M · Avg Vol: $859K/d

StockRank

P/E (TTM)

—

ROE

-28.5%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

COMPANY DESCRIPTION

Amplia Therapeutics Limited develops small-molecule focal adhesion kinase inhibitors, primarily targeting difficult-to-treat cancers such as pancreatic cancer and fibrotic diseases. The company holds exclusive intellectual property for its lead clinical candidate, AMP945, which enhances the efficacy of standard chemotherapy by targeting the tumor microenvironment. It is a highly focused oncology-biotech company advancing through Phase 2 clinical trials in high-mortality indications.

PRICE (1Y)+33.3%

SMA 50SMA 200

$0.11

RSI (14)

50.0

52W High

$0.30

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

-31.0%22.6

ROE

-28.5%26.0

GP/Assets

20.5%47.7

Op. Margin

-166.4%14.8

FCF/Assets

-46.2%5.2

Piotroski

19.2

Int. Cover

-50.0x6.1

D/E Ratio

0.01x89.3

Current Ratio

28.17x97.7

Value

P/E (TTM)

—N/A

EV/EBITDA

-5.8x25.0

P/FCF

—N/A

P/B

1.8x63.1

P/S

15.4x20.2

Div Yield

—N/A

Momentum

52W High %

35%10.4

RS 6M

—N/A

SMA 50/200

1.00x63.1

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-15%15.8

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$56M

P/E (Forward)

-6.5x

Gross Margin

94.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ATX.AX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ATX.AX	Amplia Therapeutics Limited(you)	$56M	15	STRONG SELL
PTX.AX	Prescient Therapeutics Limited	$59M	17	STRONG SELL
BOT.AX	Botanix Pharmaceuticals Limited	$51M	9	STRONG SELL
LTP.AX	LTR PHARMA FPO [LTP]	$71M	19	STRONG SELL
IMM.AX	Immutep Limited	$54M	6	STRONG SELL
ACW.AX	Actinogen Medical Limited	$87M	8	STRONG SELL
ILA.AX	Island Pharmaceuticals Limited	$76M	5	STRONG SELL
PAR.AX	Paradigm Biopharmaceuticals Limited	$70M	0	STRONG SELL
OCC.AX	Orthocell Limited	$146M	14	STRONG SELL
NYR.AX	Nyrada Inc.	$79M	1	STRONG SELL

Peer medians: ROE -19.4% · P/E 22.4x · Gross margin 49.7%

Amplia Therapeutics Limited (ATX.AX) — Stock Score Summary

Amplia Therapeutics Limited (ATX.AX) has a MoatMap StockRank of 15/100 based on Quality (40/100), Value (30/100), and Momentum (27/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$0.11
Market Cap	$56M
P/E (Forward)	-6.52
Price/Book	1.79
Return on Equity	-28.5%
Return on Invested Capital	-31.0%
Debt/Equity	0.89
Gross Margin	94.1%
Operating Margin	-166.4%
Revenue Growth	87.0%
Free Cash Flow	$-8M

Amplia Therapeutics Limited operates in the Biotechnology industry, part of the Healthcare sector (Australia).

Frequently Asked Questions

What is Amplia Therapeutics Limited’s (ATX.AX) StockRank?: MoatMap’s StockRank for Amplia Therapeutics Limited (ATX.AX) is 15/100, with a Strong Sell signal. It is a composite of Quality (40), Value (30), and Momentum (27) factor ranks across MoatMap’s 20,000+ stock universe.
Does Amplia Therapeutics Limited have an economic moat?: Amplia Therapeutics Limited (ATX.AX) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Amplia Therapeutics Limited a buy, hold, or sell?: MoatMap’s current signal for Amplia Therapeutics Limited (ATX.AX) is Strong Sell, based on a StockRank of 15/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Amplia Therapeutics Limited in?: Amplia Therapeutics Limited (ATX.AX) operates in the Healthcare sector, specifically the Biotechnology industry (Australia).